Haleon plc (HLN) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to our full year results presentation. 2025 was an important year for Halion, and we made good progress against our three strategic priorities. First, delivering competitive growth in a challenging environment. Second, unlocking productivity gains. And third, embedding an agile performance-focused culture. In terms of growth, in 2025, we delivered 3% organic sales growth, which is lower than our medium-term guidance of 4% to 6%. That was primarily the result of lower category growth than we've seen historically, which was related to our winter season portfolio, along with consumer confidence reaching multi-year lows in some of our key geographies, impacting consumer spending. Against that backdrop, our brand portfolio performed well, outperforming our global categories with 60% of the business gaining or maintaining share. We remain confident that we can continue to outperform as we focus on the key opportunities we outlined at our Capital Markets Day. Let me give you some examples. In China, we're closing the incident versus treatment gap through the launch of Paradontax. As the largest gum health market in the world, there is a significant opportunity in China, and Paradontax has become one of the top-selling innovations across China's three largest cities, Beijing, Shanghai, and Guangzhou, and now in over 10,000 stores. We're accelerating the rollout to 20 cities this year to drive further penetration. And within sensitivity, Sensodyne's expanded clinical range, including Sensodyne Clinical White, Clinical Repair, and Clinical Enamel Strength, have driven strong uptake among younger consumers. The range is now in 30 markets globally, with Sensodyne growing over 1.5 times the overall category. We're also delivering innovation-led premiumization. I...